Resources
17 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 2/9/2022 (updated 3/26/2024)
Summary of innovation abstracts that were presented at the National Academy of Medicine’s recent Stigma of Addiction Summit.
Posted 3/15/2022 (updated 3/27/2024)
Pre- Pregnancy fact sheet. Information for Providers
Posted 6/10/2022 (updated 3/27/2024)
More people are dying from overdose now than at any point in history. Individuals learned about three innovative communication campaigns that challenge stigma, center people who use drugs, and build support for harm reduction as a lifesaving strategy to reduce overdose deaths.
Posted 7/25/2022 (updated 3/27/2024)
In 2019, the Addictions, Drug & Alcohol Institute (ADAI) at the University of Washington launched the “Meds First” program to provide onsite, low-barrier access to buprenorphine in partnership with six syringe services programs across WA State. A key component of the Meds First service model was the addition of care navigation to support client engagement and retention in OUD treatment.
Posted 6/6/2022 (updated 3/27/2024)
The goal of the training was to develop knowledge and skills to discuss infectious disease/sexual health concerns and provide health promotion support in OUD settings.
Posted 11/14/2022 (updated 3/27/2024)
In their new 2022 Clinical Practice Guideline, the Centers for Disease Control and Prevention (CDC) provides updated evidence and research on the risks and benefits of prescription opioids for acute, subacute, and chronic pain. These include dosing strategies, tapering and discontinuation, comparisons with nonopioid pain treatments, and risk mitigation strategies.
Posted 1/8/2024 (updated 3/28/2024)
The Neonatal Abstinence Syndrome (NAS) Cohort I tip sheet is a result of collaborative efforts of the NAS Cohort I grant recipients. Drawing on the insights and experiences of our grantees, we identified 9 key recommendations. These tips serve not only as a guiding framework for future NAS cohort grantees but also offers valuable guidance to all RCORP grant cohorts. This resource aims to enhance effectiveness and increase the impact of all RCORP grantee initiatives.
Posted 11/19/2019 (updated 3/28/2024)
This document is to assist community leaders, local and regional organizers, non-profit groups, law enforcement, public health, and members of the public in understanding and navigating effective strategies to prevent opioid overdose in their communities.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 9/1/2021 (updated 4/2/2024)